Sernova Corp.

Working to cure diabetes

Message: Hitting the Promotion Trail down Hollywood Way ... East Hollywood, that is!
It's not a Con!!!!
LONDON, ONTARIO - TheNewswire - February 17, 2020 - Sernova Corp (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine therapeutics leader announced today that President and CEO Dr. Philip Toleikis will present at NobleCon16 on February 18th at 2:00 p.m. NobleCon16 is Noble Capital Markets' 16th Annual Investor Conference featuring emerging growth companies being held at the Seminole Hard Rock Hotel & Casino, Hollywood, Florida from February 17-18th, 2020.

A high-definition, video webcast of the presentation will be available the following day on Sernova's website and available at www.nobleconference.comand on Channelchek, Noble's investor portal


Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova's clinical trial are incapable of producing C-peptide, a biomarker for insulin produced by islet cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy.

For more information on the clinical trial A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch(TM) for Clinical Islet Transplantation, please visit

For more information on enrollment and recruitment details please visit:

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit

For further information contact:

Dominic Gray

Sernova Corp

Tel: (519) 858-5126

[email protected]


New Message
Please login to post a reply